title: Intermediate-dose (25mg/m2) IV melphalan for multiple myeloma with renal failure.
abstract: BACKGROUND
  Multiple myeloma is a malignant plasma cell disorder which still bears a dramatic prognosis. Renal insufficiency is a frequent and severe complication directly related to prognosis. The aim of our study was to establish whether an intermediate dose of intravenous melphalan, 25 mg/m2, could be safely and efficiently administered to patients with multiple myeloma and renal impairment.
  
  
  METHODS
  Between January 1990 and April 2000, 45 patients with multiple myeloma received a single intravenous dose of melphalan, 25 mg/m2. Survival was analysed, as well as the duration of response and potential toxicity. In addition, a melphalan pharmacokinetic study was performed.
  
  
  RESULTS
  The overall median survival was 45 +/- 43 months after diagnosis. Based on the Cockcroft and Gault formula, 79% patients had renal impairment. For the 28 stage III patients, survival was no different whether renal insufficiency was present or not. Twenty-five out of 34 patients had leukopenia for an average of 13.8 +/- 12 days, and the most frequent adverse effect was infection. The pharmacokinetic study showed that the melphalan area under the curve was positively correlated to the degree of renal insufficiency. However, this was not clinically relevant since patients with the most altered renal function, including those undergoing dialysis, did not present more episodes of leukopenia.
  
  
  CONCLUSIONS
  The present study shows that renal impairment is not a contraindication for aggressive myeloma chemotherapy, even for patients undergoing dialysis. Intravenous melphalan, 25 mg/m2, is associated with good survival and acceptable side-effects. A randomised trial seems needed to compare this melphalan dose with standard melphalan/prednisone or combination chemotherapies.
authors.affiliation: Services of Nephrology, Edouard Herriot Hospital, Lyon, France. cecile.vigneau@tnn.ap-hop-paris.fr
authors.forename: Cécile
authors.initials: C
authors.lastname: Vigneau
authors.forename: Claude
authors.initials: C
authors.lastname: Ardiet
authors.forename: Monique
authors.initials: M
authors.lastname: Bret
authors.forename: Maurice
authors.initials: M
authors.lastname: Laville
authors.forename: Denis
authors.initials: D
authors.lastname: Fiere
authors.forename: Brigitte
authors.initials: B
authors.lastname: Tranchand
authors.forename: Denis
authors.initials: D
authors.lastname: Fouque
mesh_terms: D000328:Adult; D000368:Aged; D015331:Cohort Studies; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D020714:Maximum Tolerated Dose; D008558:Melphalan / Q000008:administration & dosage* / Q000009:adverse effects; D008875:Middle Aged; D009101:Multiple Myeloma / Q000150:complications / Q000188:drug therapy* / Q000401:mortality*; D010865:Pilot Projects; D011336:Probability; D011379:Prognosis; D011446:Prospective Studies; D051437:Renal Insufficiency / Q000150:complications / Q000188:drug therapy* / Q000401:mortality*; D018570:Risk Assessment; D012720:Severity of Illness Index; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D008558:Melphalan